Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; RIVAL-01 (Primary)
  • Indications Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAPTOR
  • Sponsors Turnstone Biologics

Most Recent Events

  • 21 Nov 2023 Status changed from active, no longer recruiting to discontinued.
  • 08 Feb 2023 Planned End Date changed from 30 Jul 2025 to 31 Dec 2023.
  • 08 Feb 2023 Planned primary completion date changed from 30 Dec 2024 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top